You are here: Industry Insights > Seattle

News List

FDA approves Astellas-Seattle Genetics’ bladder cancer drug pharmaceutical-technology
December 23, 2019
The US Food and Drug Administration (FDA) has granted accelerated approval to Astellas Pharma and Seattle Genetics’ Padcev drug to treat locally advanced or metastatic urothelial cancer.
Seattle Genetics, Astellas Announce FDA Grants Review for Enfortumab Vedotin BLA americanpharmaceuticalreview
September 17, 2019
Seattle Genetics and Astellas Pharma announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for the investigational agent enfortumab vedotin and ...
Seattle Genetics' Adcetris posts double survival win fiercepharma
December 06, 2018
SAN DIEGO—Last month, Seattle Genetics scored an ultrafast FDA nod for Adcetris in patients with newly diagnosed peripheral T-cell lymphoma, and data presented at the American Society of Hematology annual meeting show why.
Facebook opens new AI research labs in Seattle and Pittsburgh biospectrumasia
May 11, 2018
hires AI experts from Universities;LeCun stressed that the company’s goal with its FAIR program was to create a healthy partnership between Facebook and the universities which contributed to its research labs.
Seattle Genetics gain breakthrough therapy designation pharmafile
March 27, 2018
Seattle Genetics and Astellas have confirmed that the drug candidate they are co-developing, enfortumab, has been given FDA breakthrough therapy designation.
Seattle Genetics Completes Acquisition of Cascadian Therapeutics biospace
March 12, 2018
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced it has completed its previously announced acquisition of Cascadian Therapeutics, Inc
Seattle Genetics Commences Dosing in Early-Stage Multiple Myeloma Trial biospace
March 08, 2018
Seattle Genetics, Inc. dosed its first patient with an early-stage treatment for patients with relapsed or refractory multiple myeloma (MM).
Seattle in $614m move for Cascadian Therapeutics pharmafile
February 01, 2018
Things don’t always go quite according to plan in the biotech world – something both Seattle Genetics and Cascadian Therapeutics know only too well.